OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug CandidateBusiness Wire • 01/06/26
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 01/06/26
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital HerpesBusiness Wire • 12/22/25
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients payWSJ • 12/19/25
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for AmericansBusiness Wire • 12/19/25
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & ComplianceBusiness Wire • 12/18/25
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 12/17/25
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary GoalZacks Investment Research • 12/16/25
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 TrialBusiness Wire • 12/15/25
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast CancerBusiness Wire • 12/09/25
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025Business Wire • 12/07/25
Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025Business Wire • 12/06/25
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple MyelomaBusiness Wire • 12/06/25
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25